Telix Pharmaceuticals Limited (TLPPF)
OTCMKTS · Delayed Price · Currency is USD
9.20
-0.05 (-0.54%)
Sep 3, 2025, 3:47 PM EDT
Telix Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 664.23 | 484.69 | 342.57 | 108.81 | 5.52 | 4.02 | Upgrade | |
Revenue Growth (YoY) | 55.35% | 41.49% | 214.82% | 1870.12% | 37.33% | 64.26% | Upgrade |
Cost of Revenue | 305.95 | 185.2 | 134.99 | 44.29 | 1.85 | 1.56 | Upgrade |
Gross Profit | 358.28 | 299.49 | 207.58 | 64.52 | 3.67 | 2.46 | Upgrade |
Selling, General & Admin | 168.71 | 128.18 | 84.72 | 59.2 | 34.16 | 18.88 | Upgrade |
Research & Development | 153.75 | 120.45 | 87.62 | 55.06 | 24.82 | 17.81 | Upgrade |
Other Operating Expenses | 7.72 | 0.18 | -0.13 | 0.63 | - | - | Upgrade |
Operating Expenses | 330.18 | 248.81 | 172.21 | 114.89 | 62.75 | 40.46 | Upgrade |
Operating Income | 28.1 | 50.68 | 35.37 | -50.37 | -59.08 | -38 | Upgrade |
Interest Expense | -10.64 | -4.48 | -0.53 | -0.22 | -0.12 | -0.15 | Upgrade |
Interest & Investment Income | 9.84 | 6.72 | 0.69 | 0 | - | 0.05 | Upgrade |
Currency Exchange Gain (Loss) | 13.4 | 11.58 | -0.66 | -0.76 | 1.23 | -3.04 | Upgrade |
Other Non Operating Income (Expenses) | -19.57 | -18.37 | -8.85 | -4.33 | 10.25 | 9.34 | Upgrade |
EBT Excluding Unusual Items | 21.14 | 46.12 | 26.02 | -55.68 | -47.71 | -31.79 | Upgrade |
Merger & Restructuring Charges | -5.36 | -5.06 | - | - | - | - | Upgrade |
Asset Writedown | 0.5 | 0.48 | -0.55 | - | - | - | Upgrade |
Other Unusual Items | -7.24 | -6.85 | -23.36 | -11.36 | -10.8 | -5.19 | Upgrade |
Pretax Income | 9.04 | 34.69 | 2.1 | -67.03 | -58.51 | -36.98 | Upgrade |
Income Tax Expense | -1.8 | 3.8 | -1.45 | 3.71 | 0.03 | -2.35 | Upgrade |
Net Income | 10.84 | 30.89 | 3.55 | -70.74 | -58.54 | -34.63 | Upgrade |
Net Income to Common | 10.84 | 30.89 | 3.55 | -70.74 | -58.54 | -34.63 | Upgrade |
Net Income Growth | -66.76% | 769.68% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 254 | 331 | 319 | 311 | 282 | 257 | Upgrade |
Shares Outstanding (Diluted) | 260 | 345 | 324 | 311 | 282 | 257 | Upgrade |
Shares Change (YoY) | -37.99% | 6.64% | 4.21% | 10.08% | 9.69% | 10.21% | Upgrade |
EPS (Basic) | 0.04 | 0.09 | 0.01 | -0.23 | -0.21 | -0.13 | Upgrade |
EPS (Diluted) | 0.04 | 0.09 | 0.01 | -0.23 | -0.21 | -0.14 | Upgrade |
EPS Growth | -45.24% | 715.36% | - | - | - | - | Upgrade |
Free Cash Flow | 9.64 | 17.77 | 9.68 | -48.26 | -44.11 | 1.32 | Upgrade |
Free Cash Flow Per Share | 0.04 | 0.05 | 0.03 | -0.15 | -0.16 | 0.01 | Upgrade |
Gross Margin | 53.94% | 61.79% | 60.60% | 59.29% | 66.46% | 61.17% | Upgrade |
Operating Margin | 4.23% | 10.46% | 10.32% | -46.29% | -1069.60% | -944.81% | Upgrade |
Profit Margin | 1.63% | 6.37% | 1.04% | -65.01% | -1059.90% | -861.06% | Upgrade |
Free Cash Flow Margin | 1.45% | 3.67% | 2.83% | -44.35% | -798.67% | 32.84% | Upgrade |
EBITDA | 36.41 | 54.2 | 38.97 | -47.3 | -55.79 | -34.67 | Upgrade |
EBITDA Margin | 5.48% | 11.18% | 11.38% | -43.47% | - | - | Upgrade |
D&A For EBITDA | 8.31 | 3.52 | 3.6 | 3.07 | 3.29 | 3.33 | Upgrade |
EBIT | 28.1 | 50.68 | 35.37 | -50.37 | -59.08 | -38 | Upgrade |
EBIT Margin | 4.23% | 10.46% | 10.32% | -46.29% | - | - | Upgrade |
Effective Tax Rate | - | 10.95% | - | - | - | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.